首页> 美国卫生研究院文献>Journal of the Boston Society of Medical Sciences >Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine
【2h】

Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine

机译:检测尿液中膀胱移行细胞癌的新型蛋白质组学方法的建立

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Development of noninvasive methods for the diagnosis of transitional cell carcinoma (TCC) of the bladder remains a challenge. A ProteinChip technology (surface enhanced laser desorption/ionization time of flight mass spectrometry) has recently been developed to facilitate protein profiling of biological mixtures. This report describes an exploratory study of this technology as a TCC diagnostic tool. Ninety-four urine samples from patients with TCC, patients with other urogenital diseases, and healthy donors were analyzed. Multiple protein changes were reproducibly detected in the TCC group, including five potential novel TCC biomarkers and seven protein clusters (mass range, 3.3 to 133 kd). One of the TCC biomarkers (3.4 kd) was also detected in bladder cancer cells procured from bladder barbotage and was identified as defensin. The TCC detection rates provided by the individual markers ranged from 43 to 70% and specificities from 70 to 86%. Combination of the protein biomarkers and clusters, increased significantly the sensitivity for detecting TCC to 87% with a specificity of 66%. Interestingly, this combinatorial approach provided sensitivity of 78% for detecting low-grade TCC compared to only 33% of voided urine or bladder-washing cytology. Collectively these results support the potential of this proteomic approach for the development of a highly sensitive urinary TCC diagnostic test.
机译:开发用于诊断膀胱移行细胞癌(TCC)的非侵入性方法仍然是一个挑战。最近开发了一种ProteinChip技术(表面增强的激光解吸/电离飞行时间质谱),以促进生物混合物的蛋白质谱分析。本报告介绍了对该技术作为TCC诊断工具的探索性研究。分析了来自TCC患者,其他泌尿生殖系统疾病患者和健康捐献者的94份尿液样本。在TCC组中可重复检测到多种蛋白质变化,包括五个潜在的新型TCC生物标记和七个蛋白质簇(质量范围为3.3至133 kd)。 TCC生物标志物之一(3.4 kd)在从膀胱bar船获得的膀胱癌细胞中也被检测到,并被确定为防御素。单个标记物提供的TCC检测率范围为43%至70%,特异性为70%至86%。蛋白质生物标志物和簇的组合显着提高了检测TCC的灵敏度,达到87%,特异性为66%。有趣的是,与仅33%的排尿或膀胱冲洗细胞学检查相比,这种组合方法可检测低级TCC的敏感性为78%。这些结果共同证明了这种蛋白质组学方法在开发高敏感性尿TCC诊断测试中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号